Alvea Holdings, LLC
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention (NCT05844202) | Alvea Holdings, LLC | 2022-06-27 |
Track Alvea Holdings, LLC automatically
Every clearance here is in the API, with alerts when new ones post.